NCT06916585View on ClinicalTrials.gov

Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

December 31, 2027

Conditions
Acute-On-Chronic Liver Failure
Interventions
DRUG

AS1501 for injection

Single administration, after 20 days of elution, enter continuous administration, once a week for 4 consecutive weeks

All Listed Sponsors
collaborator

Guangzhou 8th People's Hospital

OTHER

collaborator

Shenzhen Zhongke Amshenn Pharmaceutical Co., Ltd.

OTHER

lead

Shenzhen Third People's Hospital

OTHER